{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:49:13Z","timestamp":1760906953526,"version":"3.44.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.ygyno.2010.11.008","type":"journal-article","created":{"date-parts":[[2010,12,18]],"date-time":"2010-12-18T04:14:57Z","timestamp":1292645697000},"page":"454-458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)"],"prefix":"10.1016","volume":"120","author":[{"given":"Thomas J.","family":"Herzog","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen","family":"DeGeest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheldon A.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"DeBernardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel S.","family":"Lentz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2010.11.008_bb0005","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0010","article-title":"Preclinical profile of SK&F 104864, a water soluble analogue of campothecin","volume":"103","author":"Rowinsky","year":"1989"},{"issue":"Supplement 5","key":"10.1016\/j.ygyno.2010.11.008_bb0015","article-title":"Current perspectives in the treatment of ovarian cancer: an update on the role of topotecan","volume":"7","author":"Herzog","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0020","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0090-8258(03)00467-0","article-title":"Clinical experience with topotecan in relapsed ovarian cancer","volume":"90","author":"Herzog","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0025","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment or recurrent ovarian cancer","volume":"15","author":"Ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0030","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Topotecan for the treatment of advanced epithelial ovarian cancer: an open label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel","volume":"6","author":"Bookman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0035","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.1996.14.5.1552","article-title":"Phase II study of intravenous topotecan as a 5day infusion for refractory epithelial ovarian carcinoma","volume":"14","author":"Kudelka","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0040","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.1996.14.12.3056","article-title":"Topotecan, an active drug in the second line treatment of epithelial ovarian cancer: results of a large European phase II study","volume":"14","author":"Creemers","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0045","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1006\/gyno.1997.4787","article-title":"Topotecan in platinum- and paclitaxel-resistant ovarian cancer","volume":"66","author":"Swisher","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0050","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1006\/gyno.2001.6365","article-title":"Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer","volume":"83","author":"Rodriguez","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0055","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.2000.18.5.1062","article-title":"Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study","volume":"18","author":"McGuire","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0060","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ygyno.2004.08.026","article-title":"Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer","volume":"95","author":"Bhoola","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0065","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1525-1438.2007.01001.x","article-title":"A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum","volume":"18","author":"Brown","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0070","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1006\/gyno.2001.6435","article-title":"A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients","volume":"83","author":"Homesley","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0075","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ygyno.2004.09.005","article-title":"Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer","volume":"95","author":"Levy","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0080","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ygyno.2005.04.032","article-title":"Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma","volume":"98","author":"O'Malley","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000127384","article-title":"Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy","volume":"73","author":"Largillier","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ygyno.2006.11.017","article-title":"Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer","volume":"105","author":"Safra","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0095","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ygyno.2006.09.008","article-title":"A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy","volume":"104","author":"Spannuth","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1525-1438.2007.00789.x","article-title":"Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer","volume":"17","author":"Vandenput","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0105","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1525-1438.2007.01041.x","article-title":"Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer","volume":"18","author":"Le","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2007.08.062","article-title":"Weekly topotecan for recurrent platinum resistant ovarian cancer","volume":"108","author":"Abushahin","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0115","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ygyno.2008.02.028","article-title":"Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers","volume":"109","author":"Morris","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0120","article-title":"TOWER trial","author":"Sehouli","year":"2009","journal-title":"ASCO"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal 2-stage trial design for phase II trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ygyno.2010.11.008_bb0135","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810008048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810008048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:33:14Z","timestamp":1758771194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825810008048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0090825810008048"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.11.008","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}